← All trials
NCT05814159
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 24, 2022
- Primary completion
- Dec 1, 2023
- Completion date
- Mar 31, 2025
- First posted
- Apr 14, 2023
- Last posted
- Nov 9, 2023
- Enrollment
- 15
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Swedish Orphan BiovitrumLead sponsor
- CMIC Co, Ltd. JapanCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.